Merck teams with Affimed on immuno-oncology combo

John Carroll
Germany’s has inked a deal that makes it the latest in a long string of biotechs to partner up with on a combination study using the PD-1 blockbuster Keytruda.

FierceBiotech News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS